Business & Finance
Amgen reports financial results for Q2 2021
4 August 2021 -

United States-based Amgen (NASDAQ:AMGN) announced on Tuesday that it has reported its financial results for the second quarter of 2021.

The company reported an increase in total revenue by 5% to USD6.5bn in the second quarter of 2021 compared to USD6.2bn the year-ago period. A decrease in GAAP earnings per share by 73% to USD0.81 in the second quarter of 2021 compared to ISD3.05 in the year-ago period.

It posted a decrease in GAAP operating income by 64% to USD0.8bn and a decrease in GAAP operating margin by 25.8 percentage points to 13.5%.

It reported Non-GAAP EPS at USD4.38 in the second quarter of 2021, up 4% compared to USD4.20 in the year-ago period.

'We achieved solid, volume-driven growth in the quarter as our business recovered from the effects of the pandemic,' said Robert A Bradway, chairman and chief executive officer. 'As we look to the balance of the year, we are excited to be launching LUMAKRAS, a first-in-class lung cancer treatment, and advancing a robust pipeline of potential new medicines to meet the demands of patients around the world.'